Nippon India Pharma Fund(IDCW)
Ticker: mf14687
Decent
75/100
☆ Add to Watchlist
More Options
T
Tata Value Fund(Div Trig Opt A-5%)Pay
The fund shows potential but has several areas of concern that need to be addressed for better performance.
View details
T
Tata Value Fund(Div Trig Opt B-10%)Pay
..
View details
T
Tata Value Fund(Div Trig Opt A-5%)
The Tata Value Fund shows decent potential with consistent growth and manageable risks, making it a reasonable investment option.
View details
T
Tata Value Fund(Div Trig Opt B-10%)
The fund shows potential but has several areas of concern that need to be addressed for better performance.
View details
A
Axis Multicap Fund(IDCW)
The fund shows potential but faces challenges in growth consistency and market sentiment.
View details
Q
Quant Mid Cap Fund(IDCW)
The fund shows potential for moderate growth but carries certain risks that need to be monitored closely.
View details
N
Nippon India Floater Fund(IDCW)
The Nippon India Floater Fund shows moderate potential but faces challenges in growth and profitability.
View details
N
Nippon India Floater Fund(Q-IDCW)
The Nippon India Floater Fund shows decent potential but is not without its risks. Investors should be cautious and consider the volatility in profit margins and cash flow.
View details
N
Nippon India Floater Fund(W-IDCW)
The fund shows decent potential but lacks strong growth drivers and has some risks that need to be monitored.
View details
N
Nippon India Floater Fund(M-IDCW)
The Nippon India Floater Fund shows decent potential but faces challenges in growth consistency and profitability metrics.
View details
N
Nippon India Floater Fund(DD-IDCW)
The fund shows decent potential but faces challenges in profitability and market positioning.
View details
A
Aditya Birla SL Balanced Advantage Fund(IDCW-Payout)
The fund shows a decent performance with potential for growth, but investors should be cautious of execution risks.
View details
A
Aditya Birla SL Balanced Advantage Fund(IDCW)
The fund shows decent potential with a balanced approach to growth and risk management.
View details
I
Invesco India Large & Mid Cap Fund(IDCW)
The fund shows decent potential with consistent growth, but faces challenges in valuation and governance aspects.
View details
K
Kotak Aggressive Hybrid Fund(IDCW Payout)
The fund shows a decent potential for growth with manageable risks, making it a reasonable investment choice.
View details
K
Kotak Aggressive Hybrid Fund(IDCW)
The Kotak Aggressive Hybrid Fund shows decent potential with a balanced approach to growth and profitability, though some risks remain.
View details
Business Overview
Nippon India Pharma Fund (IDCW) is a dedicated mutual fund focusing on the pharmaceutical sector, ideal for investors seeking to capitalize on India's growing healthcare industry. This fund aims to provide long-term capital appreciation by investing in a diversified portfolio of pharma and healthcare stocks. With a professional management team and a robust investment strategy, it offers a reliable avenue for wealth creation.
- Focuses on the booming pharmaceutical sector
- Ideal for long-term investors
- Diversified portfolio to mitigate risks
- Managed by experienced professionals
- Potential for significant capital appreciation
Investment Thesis
Nippon India Pharma Fund stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the fund as a compelling choice for investors seeking long-term gains in the pharmaceutical sector.
- Strong backing from Nippon Life Insurance, enhancing credibility and trust.
- Significant growth potential in digital services, tapping into evolving market trends.
- Attractive valuation metrics compared to industry peers, offering a favorable entry point.
- Well-diversified portfolio with a focus on high-growth pharmaceutical companies.
- Consistent performance track record, reinforcing investor confidence.
Opportunity vs Risk
Opportunities
- Strong growth in healthcare sector
- Rising demand for pharmaceuticals
- Government support for drug manufacturing
- Innovative drug development pipeline
Risks ⚠️
- Regulatory changes affecting approvals
- Intense competition in pharma market
- Currency fluctuations impacting profits
- R&D costs may increase significantly
Peer Perspective
Nippon India Pharma Fund is currently trading at a slight premium compared to peers like SBI Mutual Fund and HDFC Mutual Fund. A sustained improvement in margin stability could trigger a rerating for this fund.
📊 Stock Investment Checklist (100 Points)
Nippon India Pharma Fund(IDCW) • Updated: 2025-10-01 06:53:02
-
10BusinessHighPharmaceutical sector is essential and has a clear model, but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
10ValuationHighP/E and P/B ratios are higher than peers, indicating potential overvaluation.
-
8BalanceHighModerate debt levels, but liquidity is a concern.
-
7GovernanceHighPromoter holding is stable, but some pledging exists.
-
8DriversHighGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 75 / 100
• Decent
The Nippon India Pharma Fund shows potential for growth but is facing challenges in profitability and valuation metrics. Investors should be cautious and monitor market conditions closely.